Key result
Statin discontinuation, even briefly, appears to increase the risk of adverse vascular outcomes, emphasizing the need for strict adherence monitoring.
Why the study?
Does statin discontinuation lead to adverse outcomes in patients on statin therapy?
Does statin discontinuation lead to adverse outcomes in patients on statin therapy?
Statin discontinuation, even briefly, may be harmful and should be avoided unless there is a compelling reason, highlighting the need for adherence monitoring.
May support adherence monitoring in statin users; hypothesis-generating from Level 5 data, needs randomized confirmation.
Statin treatment is essential for the prevention of vascular disease. Despite the established benefits of statins, discontinuation of these agents is frequent. Whether statin discontinuation leads to adverse outcomes is still debated and the most convincing evidence is mainly restricted to patients who experienced an acute vascular event. It is important to establish if this phenomenon extends to other populations, like those without vascular disease but with a high calculated risk. Overall, it appears that even a brief discontinuation of statins might be harmful. Therefore, statin treatment should not be interrupted except if there is a very good reason. Moreover, patients should be instructed as to why they must adhere to their medication. Adherence should be monitored regularly.
No takes yet. Share an insight, caveat, or question.
Τζιόμαλος et al. (2008) conducted a review in Vascular disease. Statin discontinuation vs. Statin continuation was evaluated on Adverse vascular outcomes. Statin discontinuation, even briefly, appears to increase the risk of adverse vascular outcomes, emphasizing the need for strict adherence monitoring.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: